A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.
Ventyx axes development of TYK2 inhibitor following Phase 2 failure
Ventyx Biosciences is shelving a drug after a mid-stage miss and failure. The company was investigating VTX958, an allosteric TYK2 inhibitor, in patients with moderately